Insulet shares rise 6.6% after Q3 profit tops estimates
Shares rose 6.6% in regular trading. Adjusted EPS of $1.99 beat the $1.62 consensus estimate, revenue of $842.0 million was in line with $849.34 million, and a $1 billion buyback was authorized.
Key takeaways
- Insulet (PODD) said third-quarter 2026 adjusted earnings were $1.99 per share, against a $1.62 per share consensus estimate. Revenue was $842.0 million, in line with the $849.34 million estimate. The company also authorized a $1 billion share repurchase program through Dec. 31, 2028, and set full-year revenue growth guidance at 21% to 22%.
Insulet (PODD) said on Nov. 4 that third-quarter adjusted earnings reached $1.99 per diluted share, topping the $1.62 per share consensus estimate. Revenue of $842.0 million was in line with the $849.34 million estimate. Shares rose 6.6% in regular trading as of 3:59 p.m. ET, from a previous close of $154.86.
The company sells the Omnipod tubeless insulin delivery platform for people with diabetes. It said the results covered the three months ended Sept. 30, 2026.
Here's how the company did:
- Adjusted EPS: $1.99 vs. $1.24 a year earlier, $1.62 expected
- Revenue: $842.0 million vs. $706.3 million a year earlier, $849.34 million expected
- GAAP diluted EPS: $2.03 vs. $1.24 a year earlier
Revenue rose 19.2% from a year earlier, or 19.6% in constant currency. The company said that was slightly above the top of its guidance range of 17.5% to 19.5% at constant currency rates.
Adjusted operating income was $185.2 million, or 22.0% of revenue, up 490 basis points from a year earlier. Adjusted net income rose 57.2% to $138.0 million from $87.8 million.
“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,” said President and CEO Ashley McEvoy. “We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation.”
Segment results
U.S. Omnipod revenue was $570.4 million, up 14.7% from a year earlier.
International Omnipod revenue was $266.2 million, up 31.7%, or 33.0% in constant currency.
Total Omnipod revenue was $836.6 million, up 19.7%. Drug Delivery revenue was $5.5 million.
2026 guidance
For the year ending Dec. 31, 2026, the company raised its total revenue growth forecast to 21% to 22% in constant currency, from 20% to 22% previously. It raised its adjusted operating margin outlook to about 150 basis points of year-over-year expansion, from about 100 basis points. Adjusted EPS growth guidance of more than 30% was unchanged.
| Metric | Prior guidance (Aug. 5) | New guidance (Nov. 4) |
|---|---|---|
| U.S. Omnipod | 17% to 19% | 17.5% to 18.5% |
| International Omnipod | 30% to 32% | 32% to 33% |
| Total Omnipod | 21% to 23% | 21.5% to 22.5% |
| Total revenue growth | 20% to 22% | 21% to 22% |
| Adjusted operating margin | About 100 bps expansion | About 150 bps expansion |
Capital returns
The board approved a share repurchase program of up to $1 billion of common stock through Dec. 31, 2028. The company expects to spend about $400 million under the program in the fourth quarter of 2026, using existing cash. The company said the new authorization is in addition to previously approved repurchase programs.
Free cash flow was $211.7 million in the quarter, compared with $329.5 million a year earlier. Capital expenditures were $113.9 million, up from $56.5 million.